Johnson & Johnson reports third-quarter 2026 results on October 13, placing immediate focus on the Innovative Medicine segment, where consensus estimates center near $16.6 billion, reflecting 6.6% year-over-year growth. Traders are monitoring whether oncology products such as Darzalex, Carvykti, and Erleada, alongside immunology agents including Tremfya and new launches like Icotyde, can offset the steep Stelara revenue decline from biosimilar competition. The segment posted $16.38 billion in the prior quarter, and management raised full-year sales guidance to a $101.1 billion midpoint after demonstrating consistent above-market expansion despite the loss of exclusivity. MedTech softness and margin pressure from product mix shifts add to the backdrop, with the earnings call providing the first detailed read on sequential momentum in key franchises.